Cooley Honored With Three China Business Law Awards

Beijing, Hong Kong and Shanghai – June 1, 2021 – For the third consecutive year, the China Business Law Journal has honored Cooley as part of its 2021 China Business Law Awards. The firm is one of only eight international law firms recognized with awards in the private equity & venture capital, healthcare, pharma & life sciences, and asset management categories.

The China Business Law Awards are based on direct feedback and thousands of votes and recommendations received from in-house counsel, other senior corporate executives and legal professionals from around the world. In determining the winners, the China Business Law Journal also considers each firm’s significant transactions, cases or other notable achievements in the past year.

The publication highlighted praise for Cooley from clients in each of the three categories in which the firm took home an award. “Cooley has rich experience in the PE/VC industry in the US, from fund foundation to investment and financing transactions, and has brought these experiences and professional services to China and combined them well on the ground, with obvious advantages in handling cross-border transactions, financing, securities, M&A and other transactions,” an anonymous venture capital firm client said.

The CEO of Legend Biotech, Huang Ying, added “I am satisfied with the service provided by the Cooley team on their knowledge in the field of securities and listing, their experience in working with regulators and their customer service.”

“The [team] is able to draft, revise and negotiate legal documents to as good as they can within tight project timelines,” said an anonymous biopharmaceutical company client. “They have a business mindset and are familiar with the life sciences sector.” 

Among all international law firms practicing in China, Cooley has the largest China-based offshore fund formation team representing the deepest experience and greatest reach and depth for China venture capital fund formation – especially venture firms focusing on early and growth stages. 

With offices in Beijing, Hong Kong, Shanghai and Singapore, Cooley represents a growing number of Asia’s most innovative and dynamic tech and life sciences companies, advising at all stages of their life cycle, from formation through financings and exits. The team’s in-depth subject matter knowledge and transactional prowess enables the firm to handle a raft of corporate, finance, M&A and capital markets work for international and Asia-based life sciences entities engaged in inbound and outbound work. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,200 lawyers across 17 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.